<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="other"><?properties open_access?><!-- Original-type: cy--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15756276</article-id><article-id pub-id-type="pmc">2361941</article-id><article-id pub-id-type="pii">6602438</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6602438</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Studies</subject></subj-group></article-categories><title-group><article-title>Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated <italic>in vitro</italic> investigations</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Azzabi</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>A N</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Calvert</surname><given-names>P M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Plummer</surname><given-names>E R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Todd</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Griffin</surname><given-names>M J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lind</surname><given-names>M J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Maraveyas</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Fishwick</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Calvert</surname><given-names>A H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Boddy</surname><given-names>A V</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Northern Institute for Cancer Research, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK</aff><aff id="aff2"><label>2</label>Northern Centre for Cancer Treatment, Newcastle General Hospital, Newcastle upon Tyne, UK</aff><aff id="aff3"><label>3</label>Academic Department of Oncology, The Princess Royal Hospital, Hull, UK</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:alan.boddy@ncl.ac.uk">alan.boddy@ncl.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>03</month><year>2005</year></pub-date><pub-date pub-type="collection"><day>22</day><month>03</month><year>2005</year></pub-date><pub-date pub-type="ppub"><day>28</day><month>03</month><year>2005</year></pub-date><volume>92</volume><issue>6</issue><fpage>1006</fpage><lpage>1012</lpage><history><date date-type="received"><day>11</day><month>10</month><year>2004</year></date><date date-type="rev-recd"><day>10</day><month>01</month><year>2005</year></date><date date-type="accepted"><day>11</day><month>01</month><year>2005</year></date></history><copyright-statement>Copyright 2005, Cancer Research UK</copyright-statement><copyright-year>2005</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>The purpose of this study was to determine activity of temozolomide combined with paclitaxel or epothilone B <italic>in vitro</italic>, and to investigate the combination of temozolomide with paclitaxel in a Phase I clinical trial. Melanoma cell lines A375P and DX3 were treated with temozolomide and either paclitaxel or epothilone B. Combination indices were determined to assess the degree of synergism. In a clinical study, 21 patients with malignant melanoma were treated with increasing doses of temozolomide (orally, days 1&#x02013;5), in combination with a fixed dose of paclitaxel (i.v. infusion day 1), followed by dose escalation of the latter drug. Cycles of treatment were repeated every 3 weeks. Pharmacokinetics of both agents were determined on day 1, with temozolomide pharmacokinetics also assessed on day 5. All three compounds were active against the melanoma cell lines, with epothilone B being the most potent. There was a strong degree of synergism between temozolomide and either paclitaxel or epothilone B. In the clinical study, no pharmacokinetic interaction was observed between temozolomide and paclitaxel. Dose escalation of both drugs to clinically active doses was possible, with no dose-limiting toxicities observed at 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> temozolomide and 225&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> paclitaxel. There were two partial responses out of 15 evaluable patients. One patient remains alive and symptom-free at 4 years after treatment. Temozolomide and paclitaxel may be administered safely at clinically effective doses. Further evaluation of these combinations in melanoma is warranted.</p></abstract><kwd-group><kwd>combination</kwd><kwd>pharmacokinetics</kwd><kwd>interaction</kwd><kwd>epothilone B</kwd></kwd-group></article-meta></front><body><p>Stage IV melanoma carries a very poor prognosis (<xref ref-type="other" rid="bib5">Balch <italic>et al</italic>, 2001</xref>) and a median survival of no more than 6&#x02013;9 months. The 5-year survival is at best 5&#x02013;10&#x00025; (<xref ref-type="other" rid="bib26">Lotze <italic>et al</italic>, 2001</xref>). Several drugs have been used in the treatment of stage IV melanoma, including dacarbazine (DTIC), nitrosoureas, platinum compounds and vinca alkaloids, with only modest success.</p><p>Paclitaxel (Taxol&#x02122;) is a member of the taxane group of antitumour agents. It was discovered in the early sixties by the National Cancer Institute (<xref ref-type="other" rid="bib36">Rowinsky and Donehower, 1995</xref>). Early clinical studies indicated activity against a number of tumours including ovarian, breast, lung and melanoma (<xref ref-type="other" rid="bib35">Rowinsky <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib15">Einzig <italic>et al</italic>, 1991b</xref>; <xref ref-type="other" rid="bib17">Ettinger, 1993</xref>; <xref ref-type="other" rid="bib27">Martin, 1993</xref>). Paclitaxel was first approved by the FDA in 1992 to be used as a second-line treatment for ovarian carcinoma (<xref ref-type="other" rid="bib1">Arbuck <italic>et al</italic>, 1993</xref>). Against metastatic malignant melanoma, paclitaxel has a response rate of 18&#x02013;20&#x00025; (<xref ref-type="other" rid="bib24">Legha <italic>et al</italic>, 1990</xref>; <xref ref-type="other" rid="bib14">Einzig <italic>et al</italic>, 1991a</xref>; <xref ref-type="other" rid="bib42">Wiernik and Einzig, 1993</xref>). Paclitaxel exerts its antitumour activity by binding to the <italic>&#x003b2;</italic> subunit of tubulin (<xref ref-type="other" rid="bib19">Horwitz, 1994</xref>) and stabilising microtubules. The mechanisms by which cells become resistant to paclitaxel are thought to be either due to mutations in tubulin or to overexpression of drug efflux pumps such as MDR1. The main toxicities associated with paclitaxel are: hypersensitivity reactions, neutropaenia and peripheral neuropathy, usually sensory.</p><p>Temozolomide (Temodal&#x02122;) is an oral alkylating agent, related to DTIC. After administration, temozolomide spontaneously decomposes to 5-(3-methyltriazen-l-yl)imidazole-4-carboxamide (MTIC), which then yields AIC and methyl diazonium (<xref ref-type="other" rid="bib12">Denny <italic>et al</italic>, 1994</xref>). The latter alkylates DNA, primarily at the <italic>O</italic><sup>6</sup> of guanine. Bioavailability of temozolomide is nearly 100&#x00025; when administered orally, with good distribution to tissue (<xref ref-type="other" rid="bib4">Baker <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib8">Brada <italic>et al</italic>, 1999</xref>). Activity has been demonstrated against a number of tumours (<xref ref-type="other" rid="bib7">Bleehen <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib13">Dhodapkar <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib29">Middleton <italic>et al</italic>, 2000b</xref>). In malignant melanoma, activity was comparable to that of dacarbazine (<xref ref-type="other" rid="bib28">Middleton <italic>et al</italic>, 2000a</xref>, <xref ref-type="other" rid="bib29">2000b</xref>).</p><p>Cancer cells may acquire resistance to temozolomide by a number of mechanisms, including overexpression of <italic>O</italic><sup>6</sup>-alkylguanine-DNA alkyltransferase (<xref ref-type="other" rid="bib23">Lee <italic>et al</italic>, 1994</xref>; <xref ref-type="other" rid="bib30">Middleton <italic>et al</italic>, 1998</xref>), deficiency or mutation in the mismatch repair (MMR) pathway (<xref ref-type="other" rid="bib11">D'Atri <italic>et al</italic>, 1998</xref>) and increased expression of proteins that inhibit apoptosis, such as Bcl-2 (<xref ref-type="other" rid="bib37">Selzer <italic>et al</italic>, 1998</xref>). Temozolomide is well tolerated (<xref ref-type="other" rid="bib31">Newlands <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib32">O'Reilly <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib7">Bleehen <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib13">Dhodapkar <italic>et al</italic>, 1997</xref>), with thrombocytopaenia as the main toxicity. This is usually self-limiting and most patients recover by day 28.</p><p>Individually, paclitaxel and temozolomide have modest activity against metastatic malignant melanoma. As they have different mechanisms of action, nonoverlapping toxicities and differing mechanisms of resistance, the combination of paclitaxel and temozolomide has been investigated in a Phase I study in melanoma patients. In addition to the clinical trial, <italic>in vitro</italic> growth inhibition studies were performed with the combination of temozolomide and either paclitaxel or epothilone B, a novel antimicrotubule compound (<xref ref-type="other" rid="bib34">Rothermel <italic>et al</italic>, 2003</xref>).</p><sec sec-type="methods"><title>METHODS</title><sec><title><italic>In vitro</italic> studies</title><p>Two melanoma cell lines, A375P and DX3, were cultured using RPMI 1640 culture medium with <sc>L</sc>-glutamine supplemented with 10&#x00025; foetal calf serum and penicillin/streptomycin in 5&#x00025; CO<sub>2</sub> incubators at 37&#x000b0;C. Cells were exposed to varying concentrations of temozolomide, paclitaxel or epothilone B individually for three doubling times and IC<sub>50</sub> values determined in triplicate using the SRB assay.</p><p>Drug combination studies were conducted on each cell line using either temozolomide plus paclitaxel or temozolomide plus epothilone B. In each case, cells were exposed to the two agents simultaneously. Drug concentrations used in combination were at 3, 1, 0.3, 0.1, 0.01 times the IC<sub>50</sub> concentration for each drug. Data were analysed using the Calcusyn software and the method of <xref ref-type="other" rid="bib9">Chou and Hayball (1996)</xref>. The combination index (CI) for each drug combination was calculated, where CI=1 denotes an additive effect, CI&#x0003c;1 indicates synergy and CI&#x0003e;1 suggests antagonism of effect.</p></sec><sec><title>Clinical study</title><p>The primary objectives of the study were to determine the maximum tolerated dose of the combination of paclitaxel and temozolomide, and to identify the haematological and nonhaematological toxicities of the combination. Secondary objectives were to determine the response rate and response duration from the combination, and to determine the pharmacokinetics of temozolomide and paclitaxel when given in combination.</p><p>Adult patients with a diagnosis of stage IV melanoma were included. All were chemotherapy na&#x000ef;ve, with no clinical evidence of CNS metastases, WHO performance status of 0&#x02013;2, a life expectancy of at least 12 weeks and adequate haematological, renal and hepatic function. Patients had at least one measurable lesion. All patients signed an informed consent form prior to participating in the trial, which was approved by the ethics committee of the Newcastle Hospitals Trust and of the Medical School, University of Kingston upon Hull. All patients had prestudy biochemical, clinical and radiological assessments before receiving the first cycle of chemotherapy and subsequently during the study. Toxicities were assessed using the Common Toxicity Criteria (Version 2.0).</p><p>Dose levels for the study were predefined as in <xref ref-type="fig" rid="fig1">Figure 1</xref>; however, intermediate dose levels were allowed. Paclitaxel was administered intravenously as a 3-h infusion on day one of each cycle. Standard premedications were used to prevent hypersensitivity reactions. Temozolomide was given orally on the morning of days 1&#x02013;5 at least 1&#x02009;h before or 2&#x02009;h after breakfast. Post chemotherapy, emesis was treated prophylactically, with ondansetron or metoclopramide orally.</p><p>On day 1 of cycle 1, blood samples (5&#x02009;ml) for analysis of temozolomide were collected in pre-chilled heparinised tubes at 10, 20, 30, 60, 90, 120, 150, 180, 240, 360 and 1320&#x02009;min after administration of temozolomide, plasma was separated and 2&#x02009;ml was transferred to a plastic tube containing 0.1&#x02009;ml of 8.5&#x00025; phosphoric acid. For analysis of paclitaxel, 5&#x02009;ml heparinised blood samples were taken pretreatment and at 90, 180, 185, 195, 210, 225, 240, 270, 300, 360, 420, 540, 1260 and 1620&#x02009;min from the start of infusion. Sampling for temozolomide pharmacokinetics was repeated on day 5 of cycle 1. Determinations of concentrations of paclitaxel or temozolomide in plasma were performed by HPLC, as previously described (<xref ref-type="other" rid="bib38">Siddiqui <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib16">Estlin <italic>et al</italic>, 1998</xref>).</p></sec></sec><sec><title>RESULTS</title><sec><title><italic>In vitro</italic> studies</title><p>Against the two melanoma cell lines, paclitaxel and temozolomide had very different activity. Values for IC<sub>50</sub> (mean&#x000b1;s.d.) for temozolomide (835&#x000b1;110 and 821&#x000b1;75&#x02009;<italic>&#x003bc;</italic><sc>M</sc>) and paclitaxel (15.3&#x000b1;2.5&#x02009;n<sc>M</sc> and 13.5&#x000b1;1.5n<sc>M</sc>) were similar for the DX3 and A375P cell lines. The cell lines were 30- to 40-fold more sensitive to epothilone B, with IC<sub>50</sub> values of 0.55&#x000b1;0.06 and 0.31&#x000b1;0.05&#x02009;n<sc>M</sc> against DX3 and A375P cells, respectively.</p><p>For the DX3 cell line, the combination of temozolomide with paclitaxel produced CI values ranging from 0.02 at a fractional effect (FE) of 0.65 to a CI of 0.4 at an FE of 0.95. Corresponding values for the DX3 cells with temozolomide and epothilone B were CI=0.01 (FE=0.84) and CI=0.55 (FE=0.96). In the A375P cell line, temozolomide plus paclitaxel produced a CI of 0.15 at an FE of 0.1 and 0.66 at an FE of 0.9. Corresponding values for the combination with epothilone in the A375P cells were CI=0.07 (FE=0.05) and CI=0.79 (FE=0.98). Taken together, these data suggest synergism of action of these drug combinations against these two melanoma cell lines.</p></sec><sec><title>Clinical study</title><p>A total of 22 patients (13 male and nine female subjects) with a median age of 52.5 years (range 29&#x02013;69 years) were recruited into the clinical study (<xref rid="tbl1" ref-type="table">Table 1</xref>). Patients received a total of 61 cycles of the combination chemotherapy, with an average of 2.8 cycles per patient. A total of 17 patients were assessable for toxicities and 15 patients were assessable for disease response. Six dose levels were explored (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>Four patients were withdrawn from the study due to development of brain metastases within 28 days of enrolment. One patient was consented and did not receive treatment due to bleeding skin lesions and one patient progressed clinically and was taken off study after 22 days. One patient with apparently recurrent disease was found, on review of CT scans after six cycles of treatment, to have simple liver cysts.</p><p>Of the 17 patients assessable for toxicity, two experienced neutropaenia Grade 3 (<xref rid="tbl2" ref-type="table">Table 2</xref>). There was one episode of Grade 4 neutropaenia in a patient who also had Grade 3 thrombocytopaenia and anaemia. There were also two other cases of Grade 3 thrombocytopaenia. Patients 5 and 10 required a 50&#x00025; dose reduction in temozolomide due to hematological toxicity, with patient 11 requiring a 50&#x00025; dose reduction in both drugs. Nonhematological toxicities included arthralgia, nausea and vaginal thrush. Two patients experienced an allergic reaction to Taxol, but in only one of these did this limit treatment.</p><p>Of the 15 patients assessable for response, there were two partial responses. Patient 1, who had primary disease in the gall bladder with liver secondaries, showed a sustained response with no evidence of progressive disease after nine cycles. At 4 years after starting the trial, the patient remains well with only minimal evidence of liver disease. Patient 206, whose primary site was the skin of the left shoulder, with some deposits in the left axiliary lymph node, was treated initially on dose level 6. She had a partial response after two cycles, which was sustained on CT scan after a further four cycles of treatment. This patient subsequently suffered a recurrence of disease 3 months after the end of treatment, received radiotherapy and further chemotherapy including single agent temozolomide, but died of disease progression nearly 2 years after entry into this trial. In addition, patient 5 at dose level 2 and patient 10 at dose level 4 had mixed or minor responses. Patient 204 had stable disease up to course 4, but was withdrawn from study due to brain metastases.</p></sec><sec><title>Pharmacokinetic studies</title><p>Temozolomide was administered at three different doses (100, 150 and 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup>). Although four patients were treated with 150&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> temozolomide (combined with 150&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> paclitaxel), reliable pharmacokinetic data for temozolomide were available from only one patient. One patient on dose level 3 at 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> had anomalous data, with increasing plasma concentrations throughout the sampling period. A representative graph of temozolomide and paclitaxel plasma concentrations in a patient treated at dose level 3 is shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><p>There was no significant difference among the estimates of half-life, Cl/F or Vz/F for temozolomide at these different doses of temozolomide (<xref rid="tbl3" ref-type="table">Table 3</xref>), with an apparent dose-linear increase in AUC comparing doses between 100 and 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (<xref rid="tbl3" ref-type="table">Table 3</xref>). The different doses of paclitaxel (150, 175, 200 and 225&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) administered in conjunction with the highest dose of temozolomide (200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) did not appear to influence the pharmacokinetics of the latter drug (data not shown). Comparing the pharmacokinetics of temozolomide on day 1 (with paclitaxel) and day 5 (without paclitaxel), there was no difference in <italic>C</italic><sub>max</sub> or AUC between the 2 days of study (<xref rid="tbl3" ref-type="table">Table 3</xref>).</p><p>A summary of the pharmacokinetic data for paclitaxel at each of four dose levels is given in <xref rid="tbl4" ref-type="table">Table 4</xref>. Clearance of paclitaxel was greater at the lowest dose level of 150&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (608&#x000b1;211&#x02009;ml&#x02009;min<sup>&#x02212;1</sup>, all patients dose levels 1&#x02013;3), compared to that observed at 175&#x02013;225&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> (373&#x000b1;100 to 363&#x000b1;120&#x02009;ml&#x02009;min<sup>&#x02212;1</sup>). For dose levels 1&#x02013;3, where the paclitaxel dose was held constant, but the dose of temozolomide varied from 100 to 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup>, there appears to be an increase in paclitaxel clearance as the dose of temozolomide was escalated (<xref rid="tbl4" ref-type="table">Table 4</xref>). However, the numbers of patients at each dose level are small and one-way analysis of variance on the log-transformed data indicated no significant effect. Comparison of paclitaxel clearance from patients in the current study with those from previously published studies suggests that those patients at dose level 1 have an unusually low clearance, while clearance values in patients at dose level 3 are larger than expected (see below).</p></sec></sec><sec><title>DISCUSSION</title><p>This investigation combines <italic>in vitro</italic> studies of temozolomide and tubulin binding drugs with a Phase I clinical study of temozolomide and paclitaxel in melanoma. Interest in the use of these two agents in melanoma has been stimulated by their single-agent activities (<xref ref-type="other" rid="bib42">Wiernik and Einzig, 1993</xref>) and nonoverlapping toxicities and mechanisms of resistance.</p><p><italic>In vitro</italic> studies in two melanoma cell lines showed sensitivity to temozolomide and paclitaxel in line with reported IC<sub>50</sub> values for a variety of other cell lines. Sensitivity to temozolomide is reported to depend on the activity of the repair enzyme <italic>O</italic><sup>6</sup>-alklyguanine alkyltransferase (ATase) and on mismatch repair (MMR) function (<xref ref-type="other" rid="bib33">Pepponi <italic>et al</italic>, 2003</xref>). While the MMR status of these cell lines is not known, the relatively high IC<sub>50</sub>, coupled with the low ATase activity of the A375P cell line (95&#x02009;fmol&#x02009;mg<sup>&#x02212;1</sup> protein) (<xref ref-type="other" rid="bib41">Wedge <italic>et al</italic>, 1997</xref>), may suggest a deficiency in MMR. Many tumour cells have only a moderate sensitivity to temozolomide (IC<sub>50</sub> around 10&#x02013;1000&#x02009;<italic>&#x003bc;</italic><sc>M</sc>) (<xref ref-type="other" rid="bib39">Taverna <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib33">Pepponi <italic>et al</italic>, 2003</xref>), with a greater degree of sensitivity to paclitaxel (IC<sub>50</sub> 1&#x02013;10n<sc>M</sc>) (<xref ref-type="other" rid="bib36">Rowinsky and Donehower, 1995</xref>; <xref ref-type="other" rid="bib22">Lamendola <italic>et al</italic>, 2003</xref>). Resistance of melanoma cell lines to temozolomide is associated with deficiencies in mismatch repair and/or high activity of the repair enzyme <italic>O</italic><sup>6</sup>-alkylguanine-DNA alkyltransferase (<xref ref-type="other" rid="bib33">Pepponi <italic>et al</italic>, 2003</xref>). Interestingly, these two melanoma cell lines were also sensitive to epothilone B (IC<sub>50</sub> 0.3 and 0.5&#x02009;n<sc>M</sc>). In a Phase I study of epothilone B, plasma concentrations exceeded 1&#x02009;n<sc>M</sc> for approximately 8&#x02009;h (<xref ref-type="other" rid="bib34">Rothermel <italic>et al</italic>, 2003</xref>).</p><p>The combination studies with temozolomide and either paclitaxel or epothilone B showed strong signs of synergy. At the higher dose combinations used, effectively all of the cells were killed. The mechanism of such synergy may relate to the mitotic block following paclitaxel or epothilone B treatment. It has been suggested that cells become apoptotic following escape from G2M blockade, and it may be that such cells are then sensitised to the actions of alkylating agents such as temozolomide. Previous studies have indicated additive effects of alkylating agents with paclitaxel (<xref ref-type="other" rid="bib25">Liebmann <italic>et al</italic>, 1994</xref>). Combinations of temozolomide with tubulin binders such as the agents studied here have not been reported previously and may show useful activity in other tumour types. Although only two melanoma cell lines were studied, the activity of these agents in combination, at clinically relevant concentrations, indicates that further evaluation is warranted.</p><p>The clinical study, with a dose escalation of temozolomide followed by escalation of paclitaxel, showed that in combination both drugs could be given at full therapeutic doses. Indeed, the toxicity experienced was relatively mild even at the highest dose of paclitaxel (225&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) permitted by the protocol. Although grade 3 and 4 toxicities were observed at dose level 4 (200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> temozolomide &#x0002b; 175&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> paclitaxel), none occurred at the subsequent higher dose levels. There was some evidence of cumulative toxicity, with patient 10 at dose level 4 withdrawn from treatment due to Grade 4 thrombocytopaenia after course 4. Further dose escalation may be possible, but the clinical benefit of this is unknown. A number of patients gained some clinical benefit from treatment with temozolomide and paclitaxel. Patient 1 showed a good response and went on to receive nine courses of treatment, remaining well on long-term follow-up. Patient 10 had a minor response and patient 206 had a partial response after course 3, receiving six courses in total. Patient 7 received six courses of treatment for what appeared to be a recurrence of liver metastases. However, liver scans revealed the presence of benign cysts. In this Phase I study, the primary aim was to determine the safety of temozolomide and paclitaxel in combination. Nevertheless, the level of activity observed, over a range of dose levels, is promising.</p><p>Other clinical studies of a combination of a taxane with monofunctional alkylating agent have been reported. Paclitaxel has been given at doses up to 250&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> with DTIC up to 1000&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. This combination was well tolerated, but did not show a higher response rate than either agent used alone (<xref ref-type="other" rid="bib18">Feun <italic>et al</italic>, 2002</xref>). Similarly, docetaxel has been combined with DTIC, but again the response rate was not dissimilar to single-agent therapy (<xref ref-type="other" rid="bib2">Bafaloukos <italic>et al</italic>, 2002a</xref>). The combination of temozolomide with docetaxel has recently been reported to be safe and to have good activity in a Phase II study (<xref ref-type="other" rid="bib3">Bafaloukos <italic>et al</italic>, 2002b</xref>). Dacarbazine may not be a good drug for use in these combinations as it requires metabolic activation, which may be inhibited by coadministered drugs such as the taxanes.</p><p>Recent clinical studies in malignant melanoma have explored other schedules and combinations of these two drugs. Temozolomide has been combined with thalidomide (<xref ref-type="other" rid="bib20">Hwu <italic>et al</italic>, 2003</xref>) or with interferon-<italic>&#x003b1;</italic>, using schedules similar to that used here, or with daily or three-times daily administration for 6 weeks out of eight. Most promising results have been obtained in combination with thalidomide (<xref ref-type="other" rid="bib10">Danson <italic>et al</italic>, 2003</xref>), but that combination requires further investigation. Paclitaxel has been investigated on a weekly schedule (<xref ref-type="other" rid="bib43">Zimpfer-Rechner <italic>et al</italic>, 2003</xref>) or every 4 days for three doses in a three week cycle. The latter schedule produced a 15&#x00025; response rate (<xref ref-type="other" rid="bib6">Bedikian <italic>et al</italic>, 2004</xref>). Combinations with carboplatin have also been investigated, but with no therapeutic benefit (<xref ref-type="other" rid="bib43">Zimpfer-Rechner <italic>et al</italic>, 2003</xref>). Given the results presented here, exploration of other schedules for both drugs may be beneficial.</p><p>The combination of temozolomide with paclitaxel involves the administration of one drug orally, while the other is given by a continuous 3&#x02009;h infusion. The relative timings of the two drugs may be governed by clinical concerns, such as withholding the oral drug in case a hypersensitivity reaction is seen to the intravenous one. Hypersensitivity reactions were seen in only two patients in this study. Regardless of the order of administration, there is no <italic>a priori</italic> reason to suspect a pharmacokinetic interaction between temozolomide and paclitaxel. One is eliminated almost entirely by a spontaneous chemical reaction, while the other is subject to metabolism, mediated by CYP450 enzymes, and to biliary excretion.</p><p>The pharmacokinetic parameters derived for temozolomide in combination with paclitaxel were very similar to those reported previously for temozolomide alone (<xref ref-type="other" rid="bib21">Jen <italic>et al</italic>, 2000</xref>). Also, there was no evidence of nonlinearity of pharmacokinetics as the dose of temozolomide was increased and no effect of increasing the concurrent dose of paclitaxel from 150 to 225&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>. Although at the lowest dose level of paclitaxel (150&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) there did appear to be an increase in clearance with increasing dose of temozolomide (100&#x02013;200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup>), this was not statistically significant. Previous studies with paclitaxel at a dose of 150&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> indicated a clearance of 588&#x000b1;31&#x02009;ml&#x02009;min<sup>&#x02212;1</sup> (<xref ref-type="other" rid="bib38">Siddiqui <italic>et al</italic>, 1997</xref>), almost identical to that reported at dose level 2. At dose level 3, the two patients with full paclitaxel data had unusually high clearances, but the third patient, in whom data were available only to 8&#x02009;h, had an approximate clearance value nearer to that expected. There was no evidence of increased clearance of paclitaxel in combination with the same dose of temozolomide at dose level 4. The expected phenomenon of apparent decrease in clearance with increasing dose of paclitaxel was observed, which may cloud the interpretation of any apparent interaction. This apparent nonlinearity in pharmacokinetics is now known to be due to the action of the solubilising agent Cremophor, which sequesters paclitaxel in a dose-dependent manner (<xref ref-type="other" rid="bib40">van Zuylen <italic>et al</italic>, 2001</xref>). In conclusion, in the absence of a within patient crossover study, there appears to be no pharmacokinetic interaction between temozolomide and paclitaxel when given in combination.</p><p>The <italic>in vitro</italic> data presented here indicate that the combination of temozolomide with the microtubule agent epothilone B or paclitaxel produces a synergistic inhibition of tumour cell growth. The clinical study of the combination of temozolomide with paclitaxel shows that this combination is well tolerated, not complicated by any pharmacokinetic interaction and has modest activity in a Phase I setting. Although the response rate in this Phase I study was not dissimilar to that of the individual agents, the combination of the two drugs at full therapeutic doses could be investigated further. Combinations of temozolomide with epothilone B may also be beneficial, but require initial clinical evaluation.</p></sec></body><back><ack><p>This research was supported by Cancer Research UK, and by the Libyan Government. Epothilone B was a kind gift from Novartis, Basle, Switzerland.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arbuck</surname><given-names>SG</given-names></name><name><surname>Christian</surname><given-names>MC</given-names></name><name><surname>Fisherman</surname><given-names>JS</given-names></name><name><surname>Cazenave</surname><given-names>LA</given-names></name><name><surname>Sarosy</surname><given-names>G</given-names></name><name><surname>Suffness</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Canetta</surname><given-names>R</given-names></name><name><surname>Cole</surname><given-names>KE</given-names></name><name><surname>Friedman</surname><given-names>MA</given-names></name></person-group><article-title>Clinical development of Taxol</article-title><source>J Natl Cancer Instit Monogr</source><year>1993</year><volume>15</volume><fpage>11</fpage><lpage>24</lpage><!--PubMed citation query: 'J Natl Cancer Instit Monogr||15|11||bib1|'--></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bafaloukos</surname><given-names>D</given-names></name><name><surname>Aravantinos</surname><given-names>G</given-names></name><name><surname>Fountzilas</surname><given-names>G</given-names></name><name><surname>Stathopoulos</surname><given-names>G</given-names></name><name><surname>Gogas</surname><given-names>H</given-names></name><name><surname>Samonis</surname><given-names>G</given-names></name><name><surname>Briasoulis</surname><given-names>E</given-names></name><name><surname>Mylonakis</surname><given-names>N</given-names></name><name><surname>Skarlos</surname><given-names>DV</given-names></name><name><surname>Kosmidis</surname><given-names>P</given-names></name></person-group><article-title>Docetaxel in combination with dacarbazine in patients with advanced melanoma</article-title><source>Oncology</source><year>2002a</year><volume>63</volume><fpage>333</fpage><lpage>337</lpage><!--PubMed citation query: 'Oncology||63|333||bib2|'--><pub-id pub-id-type="pmid">12417787</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bafaloukos</surname><given-names>D</given-names></name><name><surname>Gogas</surname><given-names>H</given-names></name><name><surname>Georgoulias</surname><given-names>V</given-names></name><name><surname>Briassoulis</surname><given-names>E</given-names></name><name><surname>Fountzilas</surname><given-names>G</given-names></name><name><surname>Samantas</surname><given-names>E</given-names></name><name><surname>Kalofonos</surname><given-names>C</given-names></name><name><surname>Skarlos</surname><given-names>D</given-names></name><name><surname>Karabelis</surname><given-names>A</given-names></name><name><surname>Kosmidis</surname><given-names>P</given-names></name></person-group><article-title>Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group</article-title><source>J Clin Oncol</source><year>2002b</year><volume>20</volume><fpage>420</fpage><lpage>425</lpage><!--PubMed citation query: 'J Clin Oncol||20|420||bib3|'--><pub-id pub-id-type="pmid">11786569</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>SD</given-names></name><name><surname>Wirth</surname><given-names>M</given-names></name><name><surname>Statkevich</surname><given-names>P</given-names></name><name><surname>Reidenberg</surname><given-names>P</given-names></name><name><surname>Alton</surname><given-names>K</given-names></name><name><surname>Sartorius</surname><given-names>SE</given-names></name><name><surname>Dugan</surname><given-names>M</given-names></name><name><surname>Cutler</surname><given-names>D</given-names></name><name><surname>Batra</surname><given-names>V</given-names></name><name><surname>Grochow</surname><given-names>LB</given-names></name><name><surname>Donehower</surname><given-names>RC</given-names></name><name><surname>Rowinsky</surname><given-names>EK</given-names></name></person-group><article-title>Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer</article-title><source>Clin Cancer Res</source><year>1999</year><volume>5</volume><fpage>309</fpage><lpage>317</lpage><!--PubMed citation query: 'Clin Cancer Res||5|309||bib4|'--><pub-id pub-id-type="pmid">10037179</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balch</surname><given-names>CM</given-names></name><name><surname>Soong</surname><given-names>SJ</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Reintgen</surname><given-names>DS</given-names></name><name><surname>Cascinelli</surname><given-names>N</given-names></name><name><surname>Urist</surname><given-names>M</given-names></name><name><surname>McMasters</surname><given-names>KM</given-names></name><name><surname>Ross</surname><given-names>MI</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>Coit</surname><given-names>DG</given-names></name><name><surname>Byrd</surname><given-names>D</given-names></name><name><surname>Desmond</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Lyman</surname><given-names>GH</given-names></name><name><surname>Morabito</surname><given-names>A</given-names></name></person-group><article-title>Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><fpage>3622</fpage><lpage>3634</lpage><!--PubMed citation query: 'J Clin Oncol||19|3622||bib5|'--><pub-id pub-id-type="pmid">11504744</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bedikian</surname><given-names>AY</given-names></name><name><surname>Plager</surname><given-names>C</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Eton</surname><given-names>O</given-names></name><name><surname>Ellerhorst</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>T</given-names></name></person-group><article-title>Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma</article-title><source>Melanoma Res</source><year>2004</year><volume>14</volume><fpage>63</fpage><lpage>66</lpage><!--PubMed citation query: 'Melanoma Res||14|63||bib6|'--><pub-id pub-id-type="pmid">15091196</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bleehen</surname><given-names>NM</given-names></name><name><surname>Newlands</surname><given-names>ES</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Selby</surname><given-names>P</given-names></name><name><surname>Calvert</surname><given-names>AH</given-names></name><name><surname>Rustin</surname><given-names>GJ</given-names></name><name><surname>Brampton</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>MF</given-names></name></person-group><article-title>Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>910</fpage><lpage>913</lpage><!--PubMed citation query: 'J Clin Oncol||13|910||bib7|'--><pub-id pub-id-type="pmid">7707118</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brada</surname><given-names>M</given-names></name><name><surname>Judson</surname><given-names>I</given-names></name><name><surname>Beale</surname><given-names>P</given-names></name><name><surname>Moore</surname><given-names>S</given-names></name><name><surname>Reidenberg</surname><given-names>P</given-names></name><name><surname>Statkevich</surname><given-names>P</given-names></name><name><surname>Dugan</surname><given-names>M</given-names></name><name><surname>Batra</surname><given-names>V</given-names></name><name><surname>Cutler</surname><given-names>D</given-names></name></person-group><article-title>Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies</article-title><source>Br J Cancer</source><year>1999</year><volume>81</volume><fpage>1022</fpage><lpage>1030</lpage><!--PubMed citation query: 'Br J Cancer||81|1022||bib8|'--><pub-id pub-id-type="pmid">10576660</pub-id></citation></ref><ref id="bib9"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>TC</given-names></name><name><surname>Hayball</surname><given-names>MP</given-names></name></person-group><article-title/><source>CalcuSyn: Windows Software for Dose Effect Analysis</source><year>1996</year><publisher-name>BIOSOFT: Cambridge, UK</publisher-name></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danson</surname><given-names>S</given-names></name><name><surname>Lorigan</surname><given-names>P</given-names></name><name><surname>Arance</surname><given-names>A</given-names></name><name><surname>Clamp</surname><given-names>A</given-names></name><name><surname>Ranson</surname><given-names>M</given-names></name><name><surname>Hodgetts</surname><given-names>J</given-names></name><name><surname>Lomax</surname><given-names>L</given-names></name><name><surname>Ashcroft</surname><given-names>L</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Middleton</surname><given-names>MR</given-names></name></person-group><article-title>Randomized phase II study of temozolomide given every 8&#x02009;h or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>2551</fpage><lpage>2557</lpage><!--PubMed citation query: 'J Clin Oncol||21|2551||bib10|'--><pub-id pub-id-type="pmid">12829675</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Atri</surname><given-names>S</given-names></name><name><surname>Tentori</surname><given-names>L</given-names></name><name><surname>Lacal</surname><given-names>PM</given-names></name><name><surname>Graziani</surname><given-names>G</given-names></name><name><surname>Pagani</surname><given-names>E</given-names></name><name><surname>Benincasa</surname><given-names>E</given-names></name><name><surname>Zambruno</surname><given-names>G</given-names></name><name><surname>Bonmassar</surname><given-names>E</given-names></name><name><surname>Jiricny</surname><given-names>J</given-names></name></person-group><article-title>Involvement of the mismatch repair system in temozolomide-induced apoptosis</article-title><source>Mol Pharmacol</source><year>1998</year><volume>54</volume><fpage>334</fpage><lpage>341</lpage><!--PubMed citation query: 'Mol Pharmacol||54|334||bib11|'--><pub-id pub-id-type="pmid">9687575</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denny</surname><given-names>BJ</given-names></name><name><surname>Wheelhouse</surname><given-names>RT</given-names></name><name><surname>Stevens</surname><given-names>MF</given-names></name><name><surname>Tsang</surname><given-names>LL</given-names></name><name><surname>Slack</surname><given-names>JA</given-names></name></person-group><article-title>NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA</article-title><source>Biochemistry</source><year>1994</year><volume>33</volume><fpage>9045</fpage><lpage>9051</lpage><!--PubMed citation query: 'Biochemistry||33|9045||bib12|'--><pub-id pub-id-type="pmid">8049205</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhodapkar</surname><given-names>M</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name><name><surname>Reid</surname><given-names>JM</given-names></name><name><surname>Burch</surname><given-names>PA</given-names></name><name><surname>Pitot</surname><given-names>HC</given-names></name><name><surname>Buckner</surname><given-names>JC</given-names></name><name><surname>Ames</surname><given-names>MM</given-names></name><name><surname>Suman</surname><given-names>VJ</given-names></name></person-group><article-title>Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><fpage>1093</fpage><lpage>1100</lpage><!--PubMed citation query: 'Clin Cancer Res||3|1093||bib13|'--><pub-id pub-id-type="pmid">9815788</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Einzig</surname><given-names>AI</given-names></name><name><surname>Hochster</surname><given-names>H</given-names></name><name><surname>Wiernik</surname><given-names>PH</given-names></name><name><surname>Trump</surname><given-names>DL</given-names></name><name><surname>Dutcher</surname><given-names>JP</given-names></name><name><surname>Garowski</surname><given-names>E</given-names></name><name><surname>Sasloff</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>TJ</given-names></name></person-group><article-title>A phase II study of taxol in patients with malignant melanoma</article-title><source>Invest New Drugs</source><year>1991a</year><volume>9</volume><fpage>59</fpage><lpage>64</lpage><!--PubMed citation query: 'Invest New Drugs||9|59||bib14|'--><pub-id pub-id-type="pmid">1673965</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Einzig</surname><given-names>AI</given-names></name><name><surname>Wiernik</surname><given-names>PH</given-names></name><name><surname>Schwartz</surname><given-names>EL</given-names></name></person-group><article-title>Taxol: a new agent active in melanoma and ovarian cancer</article-title><source>Cancer Treat Res</source><year>1991b</year><volume>58</volume><fpage>89</fpage><lpage>100</lpage><!--PubMed citation query: 'Cancer Treat Res||58|89||bib15|'--><pub-id pub-id-type="pmid">1683787</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Estlin</surname><given-names>EJ</given-names></name><name><surname>Lashford</surname><given-names>L</given-names></name><name><surname>Ablett</surname><given-names>S</given-names></name><name><surname>Price</surname><given-names>L</given-names></name><name><surname>Gowing</surname><given-names>R</given-names></name><name><surname>Gholkar</surname><given-names>A</given-names></name><name><surname>Kohler</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>IJ</given-names></name><name><surname>Morland</surname><given-names>B</given-names></name><name><surname>Pinkerton</surname><given-names>CR</given-names></name><name><surname>Stevens</surname><given-names>MC</given-names></name><name><surname>Mott</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>R</given-names></name><name><surname>Newell</surname><given-names>DR</given-names></name><name><surname>Walker</surname><given-names>D</given-names></name><name><surname>Dicks-Mireaux</surname><given-names>C</given-names></name><name><surname>McDowell</surname><given-names>H</given-names></name><name><surname>Reidenberg</surname><given-names>P</given-names></name><name><surname>Statkevich</surname><given-names>P</given-names></name><name><surname>Marco</surname><given-names>A</given-names></name><name><surname>Batra</surname><given-names>V</given-names></name><name><surname>Dugan</surname><given-names>M</given-names></name><name><surname>Pearson</surname><given-names>AD</given-names></name></person-group><article-title>Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group</article-title><source>Br J Cancer</source><year>1998</year><volume>78</volume><fpage>652</fpage><lpage>661</lpage><!--PubMed citation query: 'Br J Cancer||78|652||bib16|'--><pub-id pub-id-type="pmid">9744506</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ettinger</surname><given-names>DS</given-names></name></person-group><article-title>Overview of paclitaxel (Taxol) in advanced lung cancer</article-title><source>Semin Oncol</source><year>1993</year><volume>20</volume><fpage>46</fpage><lpage>49</lpage><!--PubMed citation query: 'Semin Oncol||20|46||bib17|'--></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feun</surname><given-names>LG</given-names></name><name><surname>Savaraj</surname><given-names>N</given-names></name><name><surname>Hurley</surname><given-names>J</given-names></name><name><surname>Marini</surname><given-names>A</given-names></name></person-group><article-title>Phase II trial of paclitaxel and dacarbazine with filgrastim administration in advanced malignant melanoma</article-title><source>Cancer Invest</source><year>2002</year><volume>20</volume><fpage>357</fpage><lpage>361</lpage><!--PubMed citation query: 'Cancer Invest||20|357||bib18|'--><pub-id pub-id-type="pmid">12025231</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horwitz</surname><given-names>SB</given-names></name></person-group><article-title>Taxol (paclitaxel): mechanisms of action</article-title><source>Ann Oncol</source><year>1994</year><volume>5</volume><fpage>S3</fpage><lpage>S6</lpage><!--PubMed citation query: 'Ann Oncol||5|S3||bib19|'--></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hwu</surname><given-names>WJ</given-names></name><name><surname>Krown</surname><given-names>SE</given-names></name><name><surname>Menell</surname><given-names>JH</given-names></name><name><surname>Panageas</surname><given-names>KS</given-names></name><name><surname>Merrell</surname><given-names>J</given-names></name><name><surname>Lamb</surname><given-names>LA</given-names></name><name><surname>Williams</surname><given-names>LJ</given-names></name><name><surname>Quinn</surname><given-names>CJ</given-names></name><name><surname>Foster</surname><given-names>T</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Livingston</surname><given-names>PO</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Houghton</surname><given-names>AN</given-names></name></person-group><article-title>Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>3351</fpage><lpage>3356</lpage><!--PubMed citation query: 'J Clin Oncol||21|3351||bib20|'--><pub-id pub-id-type="pmid">12947072</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jen</surname><given-names>JF</given-names></name><name><surname>Cutler</surname><given-names>DL</given-names></name><name><surname>Pai</surname><given-names>SM</given-names></name><name><surname>Batra</surname><given-names>VK</given-names></name><name><surname>Affrime</surname><given-names>MB</given-names></name><name><surname>Zambas</surname><given-names>DN</given-names></name><name><surname>Heft</surname><given-names>S</given-names></name><name><surname>Hajian</surname><given-names>G</given-names></name></person-group><article-title>Population pharmacokinetics of temozolomide in cancer patients</article-title><source>Pharmaceut Res</source><year>2000</year><volume>17</volume><fpage>1284</fpage><lpage>1289</lpage><!--PubMed citation query: 'Pharmaceut Res||17|1284||bib21|'--></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lamendola</surname><given-names>DE</given-names></name><name><surname>Duan</surname><given-names>ZF</given-names></name><name><surname>Yusuf</surname><given-names>RZ</given-names></name><name><surname>Seiden</surname><given-names>MV</given-names></name></person-group><article-title>Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>2200</fpage><lpage>2205</lpage><!--PubMed citation query: 'Cancer Res||63|2200||bib22|'--><pub-id pub-id-type="pmid">12727840</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Crowther</surname><given-names>D</given-names></name><name><surname>Margison</surname><given-names>GP</given-names></name></person-group><article-title>Inactivation of <italic>O</italic><sup>6</sup>-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide</article-title><source>Br J Cancer</source><year>1994</year><volume>69</volume><fpage>452</fpage><lpage>456</lpage><!--PubMed citation query: 'Br J Cancer||69|452||bib23|'--><pub-id pub-id-type="pmid">8123472</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Legha</surname><given-names>SS</given-names></name><name><surname>Ring</surname><given-names>S</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Raber</surname><given-names>M</given-names></name><name><surname>Benjamin</surname><given-names>RS</given-names></name></person-group><article-title>A phase II trial of taxol in metastatic melanoma</article-title><source>Cancer</source><year>1990</year><volume>65</volume><fpage>2478</fpage><lpage>2481</lpage><!--PubMed citation query: 'Cancer||65|2478||bib24|'--><pub-id pub-id-type="pmid">1970948</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liebmann</surname><given-names>JE</given-names></name><name><surname>Fisher</surname><given-names>J</given-names></name><name><surname>Teague</surname><given-names>D</given-names></name><name><surname>Cook</surname><given-names>JA</given-names></name></person-group><article-title>Sequence dependence of paclitaxel (Taxol(R)) combined with cisplatin or alkylators in human cancer cells</article-title><source>Oncol Res</source><year>1994</year><volume>6</volume><fpage>25</fpage><lpage>31</lpage><!--PubMed citation query: 'Oncol Res||6|25||bib25|'--><pub-id pub-id-type="pmid">7919549</pub-id></citation></ref><ref id="bib26"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Lotze</surname><given-names>MT</given-names></name><name><surname>Dallal</surname><given-names>RM</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>C</surname><given-names>FJ</given-names></name></person-group><article-title>Cutaneous melanoma</article-title><source>Cancer: Principles &#x00026; Practice of Oncology</source><year>2001</year><publisher-name>London, Philadelphia: Lippincott-Raven</publisher-name>Rosenberg SA, DeVita VT, Hellman S (eds)</citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>V</given-names></name></person-group><article-title>Overview of paclitaxel (TAXOL)</article-title><source>Semin Oncol Nurs</source><year>1993</year><volume>9</volume><fpage>2</fpage><lpage>5</lpage><!--PubMed citation query: 'Semin Oncol Nurs||9|2||bib27|'--><pub-id pub-id-type="pmid">7904376</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Middleton</surname><given-names>MR</given-names></name><name><surname>Grob</surname><given-names>JJ</given-names></name><name><surname>Aaronson</surname><given-names>N</given-names></name><name><surname>Fierlbeck</surname><given-names>G</given-names></name><name><surname>Tilgen</surname><given-names>W</given-names></name><name><surname>Seiter</surname><given-names>S</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Aamdal</surname><given-names>S</given-names></name><name><surname>Cebon</surname><given-names>J</given-names></name><name><surname>Coates</surname><given-names>A</given-names></name><name><surname>Dreno</surname><given-names>B</given-names></name><name><surname>Henz</surname><given-names>M</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>Kapp</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>J</given-names></name><name><surname>Fraass</surname><given-names>U</given-names></name><name><surname>Statkevich</surname><given-names>P</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name></person-group><article-title>Randomized phase III study of temozolomide <italic>versus</italic> dacarbazine in the treatment of patients with advanced metastatic malignant melanoma</article-title><source>J Clin Oncol</source><year>2000a</year><volume>18</volume><fpage>158</fpage><lpage>166</lpage><!--PubMed citation query: 'J Clin Oncol||18|158||bib28|'--><pub-id pub-id-type="pmid">10623706</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Middleton</surname><given-names>MR</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Arance</surname><given-names>A</given-names></name><name><surname>Wood</surname><given-names>M</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Margison</surname><given-names>GP</given-names></name></person-group><article-title><italic>O</italic><sup>6</sup>-methylguanine formation, repair protein depletion and clinical outcome with a 4&#x02009;h schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study</article-title><source>Int J Cancer</source><year>2000b</year><volume>88</volume><fpage>469</fpage><lpage>473</lpage><!--PubMed citation query: 'Int J Cancer||88|469||bib29|'--><pub-id pub-id-type="pmid">11054678</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Middleton</surname><given-names>MR</given-names></name><name><surname>Lunn</surname><given-names>JM</given-names></name><name><surname>Morris</surname><given-names>C</given-names></name><name><surname>Rustin</surname><given-names>G</given-names></name><name><surname>Wedge</surname><given-names>SR</given-names></name><name><surname>Brampton</surname><given-names>MH</given-names></name><name><surname>Lind</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>SM</given-names></name><name><surname>Newell</surname><given-names>DR</given-names></name><name><surname>Bleehen</surname><given-names>NM</given-names></name><name><surname>Newlands</surname><given-names>ES</given-names></name><name><surname>Calvert</surname><given-names>AH</given-names></name><name><surname>Margison</surname><given-names>GP</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name></person-group><article-title><italic>O</italic><sup>6</sup>-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma</article-title><source>Br J Cancer</source><year>1998</year><volume>78</volume><fpage>1199</fpage><lpage>1202</lpage><!--PubMed citation query: 'Br J Cancer||78|1199||bib30|'--><pub-id pub-id-type="pmid">9820180</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newlands</surname><given-names>ES</given-names></name><name><surname>Blackledge</surname><given-names>GR</given-names></name><name><surname>Slack</surname><given-names>JA</given-names></name><name><surname>Rustin</surname><given-names>GJ</given-names></name><name><surname>Smith</surname><given-names>DB</given-names></name><name><surname>Stuart</surname><given-names>NS</given-names></name><name><surname>Quarterman</surname><given-names>CP</given-names></name><name><surname>Hoffman</surname><given-names>R</given-names></name><name><surname>Stevens</surname><given-names>MF</given-names></name><name><surname>Brampton</surname><given-names>MH</given-names></name></person-group><article-title>Phase I trial of temozolomide (CCRG 81045: M&#x00026;B 39831: NSC 362856)</article-title><source>Br J Cancer</source><year>1992</year><volume>65</volume><fpage>287</fpage><lpage>291</lpage><!--PubMed citation query: 'Br J Cancer||65|287||bib31|'--><pub-id pub-id-type="pmid">1739631</pub-id></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Reilly</surname><given-names>SM</given-names></name><name><surname>Newlands</surname><given-names>ES</given-names></name><name><surname>Glaser</surname><given-names>MG</given-names></name><name><surname>Brampton</surname><given-names>M</given-names></name><name><surname>Rice-Edwards</surname><given-names>JM</given-names></name><name><surname>Illingworth</surname><given-names>RD</given-names></name><name><surname>Richards</surname><given-names>PG</given-names></name><name><surname>Kennard</surname><given-names>C</given-names></name><name><surname>Colquhoun</surname><given-names>IR</given-names></name><name><surname>Lewis</surname><given-names>P</given-names></name></person-group><article-title>Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours</article-title><source>Eur J Cancer</source><year>1993</year><volume>29A</volume><fpage>940</fpage><lpage>942</lpage><!--PubMed citation query: 'Eur J Cancer||29A|940||bib32|'--><pub-id pub-id-type="pmid">8499146</pub-id></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pepponi</surname><given-names>R</given-names></name><name><surname>Marra</surname><given-names>G</given-names></name><name><surname>Fuggetta</surname><given-names>MP</given-names></name><name><surname>Falcinelli</surname><given-names>S</given-names></name><name><surname>Pagani</surname><given-names>E</given-names></name><name><surname>Bonmassar</surname><given-names>E</given-names></name><name><surname>Jiricny</surname><given-names>J</given-names></name><name><surname>D'Atri</surname><given-names>S</given-names></name></person-group><article-title>The effect of <italic>O</italic>-6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)-1-nitrosourea, and cisplatin</article-title><source>J Pharmacol Exp Therapeut</source><year>2003</year><volume>304</volume><fpage>661</fpage><lpage>668</lpage><!--PubMed citation query: 'J Pharmacol Exp Therapeut||304|661||bib33|'--></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothermel</surname><given-names>J</given-names></name><name><surname>Wartmann</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Hohneker</surname><given-names>J</given-names></name></person-group><article-title>EPO906 (epohtilone B): a promising novel microtubule stabilizer</article-title><source>Semin Oncol</source><year>2003</year><volume>30</volume><fpage>51</fpage><lpage>55</lpage><!--PubMed citation query: 'Semin Oncol||30|51||bib34|'--><pub-id pub-id-type="pmid">12802795</pub-id></citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rowinsky</surname><given-names>EK</given-names></name><name><surname>Cazenave</surname><given-names>LA</given-names></name><name><surname>Donehower</surname><given-names>RC</given-names></name></person-group><article-title>Taxol: a novel investigational antimicrotubule agent</article-title><source>J Natl Cancer Instit</source><year>1990</year><volume>82</volume><fpage>1247</fpage><lpage>1259</lpage><!--PubMed citation query: 'J Natl Cancer Instit||82|1247||bib35|'--></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rowinsky</surname><given-names>EK</given-names></name><name><surname>Donehower</surname><given-names>RC</given-names></name></person-group><article-title>Paclitaxel (taxol)</article-title><source>N Engl J Med</source><year>1995</year><volume>332</volume><fpage>1004</fpage><lpage>1014</lpage><!--PubMed citation query: 'N Engl J Med||332|1004||bib36|'--><pub-id pub-id-type="pmid">7885406</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selzer</surname><given-names>E</given-names></name><name><surname>Schlagbauer-Wadl</surname><given-names>H</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name><name><surname>Pehamberger</surname><given-names>H</given-names></name><name><surname>Potter</surname><given-names>R</given-names></name><name><surname>Jansen</surname><given-names>B</given-names></name></person-group><article-title>Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines</article-title><source>Melanoma Res</source><year>1998</year><volume>8</volume><fpage>197</fpage><lpage>203</lpage><!--PubMed citation query: 'Melanoma Res||8|197||bib37|'--><pub-id pub-id-type="pmid">9664140</pub-id></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>N</given-names></name><name><surname>Boddy</surname><given-names>AV</given-names></name><name><surname>Thomas</surname><given-names>HD</given-names></name><name><surname>Bailey</surname><given-names>NP</given-names></name><name><surname>Robson</surname><given-names>L</given-names></name><name><surname>Lind</surname><given-names>MJ</given-names></name><name><surname>Calvert</surname><given-names>AH</given-names></name></person-group><article-title>A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer</article-title><source>Br J Cancer</source><year>1997</year><volume>75</volume><fpage>287</fpage><lpage>294</lpage><!--PubMed citation query: 'Br J Cancer||75|287||bib38|'--><pub-id pub-id-type="pmid">9010040</pub-id></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taverna</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Hanson</surname><given-names>AJ</given-names></name><name><surname>Monks</surname><given-names>A</given-names></name><name><surname>Gerson</surname><given-names>SL</given-names></name></person-group><article-title>Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen</article-title><source>Cancer Chemother Pharmacol</source><year>2000</year><volume>46</volume><fpage>507</fpage><lpage>516</lpage><!--PubMed citation query: 'Cancer Chemother Pharmacol||46|507||bib39|'--><pub-id pub-id-type="pmid">11138465</pub-id></citation></ref><ref id="bib40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Zuylen</surname><given-names>L</given-names></name><name><surname>Karlsson</surname><given-names>MO</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Brouwer</surname><given-names>E</given-names></name><name><surname>de Bruijn</surname><given-names>P</given-names></name><name><surname>Nooter</surname><given-names>K</given-names></name><name><surname>Stoter</surname><given-names>G</given-names></name><name><surname>Sparreboom</surname><given-names>A</given-names></name></person-group><article-title>Pharmacokinetic modelling of paclitaxel encapsulation in Cremophor EL micelles</article-title><source>Cancer Chemother Pharmacol</source><year>2001</year><volume>47</volume><fpage>309</fpage><lpage>318</lpage><!--PubMed citation query: 'Cancer Chemother Pharmacol||47|309||bib40|'--><pub-id pub-id-type="pmid">11345647</pub-id></citation></ref><ref id="bib41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wedge</surname><given-names>SR</given-names></name><name><surname>Porteous</surname><given-names>JK</given-names></name><name><surname>Newlands</surname><given-names>ES</given-names></name></person-group><article-title>Effect of single and multiple administration of an <italic>O</italic>-6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model</article-title><source>Cancer Chemoth Pharmacol</source><year>1997</year><volume>40</volume><fpage>266</fpage><lpage>272</lpage><!--PubMed citation query: 'Cancer Chemoth Pharmacol||40|266||bib41|'--></citation></ref><ref id="bib42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiernik</surname><given-names>PH</given-names></name><name><surname>Einzig</surname><given-names>AI</given-names></name></person-group><article-title>Taxol in malignant melanoma</article-title><source>J Natl Cancer Instit Monogr</source><year>1993</year><volume>15</volume><fpage>185</fpage><lpage>187</lpage><!--PubMed citation query: 'J Natl Cancer Instit Monogr||15|185||bib42|'--></citation></ref><ref id="bib43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zimpfer-Rechner</surname><given-names>C</given-names></name><name><surname>Hofmann</surname><given-names>U</given-names></name><name><surname>Figl</surname><given-names>R</given-names></name><name><surname>Becker</surname><given-names>JC</given-names></name><name><surname>Trefzer</surname><given-names>U</given-names></name><name><surname>Keller</surname><given-names>I</given-names></name><name><surname>Hauschild</surname><given-names>A</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name></person-group><article-title>Randomized phase II study of weekly paclitaxel <italic>versus</italic> paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG)</article-title><source>Melanoma Res</source><year>2003</year><volume>13</volume><fpage>531</fpage><lpage>536</lpage><!--PubMed citation query: 'Melanoma Res||13|531||bib43|'--><pub-id pub-id-type="pmid">14512795</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Dose escalation scheme, indicating daily dose of temozolomide, given on each of 5 consecutive days. Dose of paclitaxel administered on day 1. The dose levels used in the current study are indicated by number. Dose level 4 represents full therapeutic doses of each agent. After dose level 4, subsequent dose changes depended on the occurrence of dose-limiting toxicities to define the maximum tolerated dose (MTD).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="92-6602438f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Time course of temozolomide (left axis) and paclitaxel (right axis) plasma concentrations on day 1 of therapy. The oral dose of temozolomide was administered first, with the 3&#x02009;h infusion of paclitaxel started 60&#x02009;min later. Data from day 5 administration of temozolomide are superimposed for comparison.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="92-6602438f2"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Patient summary</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="center"/><col align="char" char="."/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Patient</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Dose level</bold></th><th align="center" valign="top" charoff="50"><bold>Gender</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Age (years)</bold></th><th align="left" valign="top" charoff="50"><bold>Clinical outcome</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">1</td><td align="char" valign="top" char="." charoff="50">1</td><td align="center" valign="top" charoff="50">F</td><td align="char" valign="top" char="." charoff="50">51</td><td align="left" valign="top" charoff="50">Excellent response to treatment, had nine cycles</td></tr><tr><td align="left" valign="top" charoff="50">2</td><td align="char" valign="top" char="." charoff="50">1</td><td align="center" valign="top" charoff="50">F</td><td align="char" valign="top" char="." charoff="50">62</td><td align="left" valign="top" charoff="50">PD after C2</td></tr><tr><td align="left" valign="top" charoff="50">3</td><td align="char" valign="top" char="." charoff="50">1</td><td align="center" valign="top" charoff="50">F</td><td align="char" valign="top" char="." charoff="50">57</td><td align="left" valign="top" charoff="50">PD after C4</td></tr><tr><td align="left" valign="top" charoff="50">4</td><td align="char" valign="top" char="." charoff="50">2</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">31</td><td align="left" valign="top" charoff="50">Withdrawn due to brain metastases</td></tr><tr><td align="left" valign="top" charoff="50">5</td><td align="char" valign="top" char="." charoff="50">2</td><td align="center" valign="top" charoff="50">F</td><td align="char" valign="top" char="." charoff="50">41</td><td align="left" valign="top" charoff="50">Improvement in CT after C3, but PD after C5</td></tr><tr><td align="left" valign="top" charoff="50">6</td><td align="char" valign="top" char="." charoff="50">2</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">55</td><td align="left" valign="top" charoff="50">PD after 22 days</td></tr><tr><td align="left" valign="top" charoff="50">7</td><td align="char" valign="top" char="." charoff="50">2</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">37</td><td align="left" valign="top" charoff="50">After C6, MRI revealed cysts and no cancer</td></tr><tr><td align="left" valign="top" charoff="50">8</td><td align="char" valign="top" char="." charoff="50">3</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">55</td><td align="left" valign="top" charoff="50">PD after 31 days</td></tr><tr><td align="left" valign="top" charoff="50">9</td><td align="char" valign="top" char="." charoff="50">3</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">52</td><td align="left" valign="top" charoff="50">PD after C2</td></tr><tr><td align="left" valign="top" charoff="50">10</td><td align="char" valign="top" char="." charoff="50">4</td><td align="center" valign="top" charoff="50">F</td><td align="char" valign="top" char="." charoff="50">50</td><td align="left" valign="top" charoff="50">Minor response after C3. Withdrawn due to G4 thrombocytopenia after C4</td></tr><tr><td align="left" valign="top" charoff="50">11</td><td align="char" valign="top" char="." charoff="50">4</td><td align="center" valign="top" charoff="50">F</td><td align="char" valign="top" char="." charoff="50">52</td><td align="left" valign="top" charoff="50">Stopped after C2 due to haematoxocity and allergic reaction to taxol</td></tr><tr><td align="left" valign="top" charoff="50">12</td><td align="char" valign="top" char="." charoff="50">4</td><td align="center" valign="top" charoff="50">F</td><td align="char" valign="top" char="." charoff="50">66</td><td align="left" valign="top" charoff="50">PD after C3</td></tr><tr><td align="left" valign="top" charoff="50">201</td><td align="char" valign="top" char="." charoff="50">4</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">65</td><td align="left" valign="top" charoff="50">PD after C2</td></tr><tr><td align="left" valign="top" charoff="50">13</td><td align="char" valign="top" char="." charoff="50">4</td><td align="center" valign="top" charoff="50">F</td><td align="char" valign="top" char="." charoff="50">38</td><td align="left" valign="top" charoff="50">Withdrawn due to brain metastases after C3</td></tr><tr><td align="left" valign="top" charoff="50">14</td><td align="char" valign="top" char="." charoff="50">4</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">29</td><td align="left" valign="top" charoff="50">Not given treatment, bleeding lesion</td></tr><tr><td align="left" valign="top" charoff="50">202</td><td align="char" valign="top" char="." charoff="50">4</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">53</td><td align="left" valign="top" charoff="50">PD after C2</td></tr><tr><td align="left" valign="top" charoff="50">203</td><td align="char" valign="top" char="." charoff="50">5</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">68</td><td align="left" valign="top" charoff="50">Withdrawn due to brain metastases after C1</td></tr><tr><td align="left" valign="top" charoff="50">204</td><td align="char" valign="top" char="." charoff="50">5</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">63</td><td align="left" valign="top" charoff="50">SD after C2 and C4, but withdrawn due to brain metastases after C4</td></tr><tr><td align="left" valign="top" charoff="50">205</td><td align="char" valign="top" char="." charoff="50">5</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">54</td><td align="left" valign="top" charoff="50">Withdrawn due to brain metastases after C1</td></tr><tr><td align="left" valign="top" charoff="50">206</td><td align="char" valign="top" char="." charoff="50">6</td><td align="center" valign="top" charoff="50">F</td><td align="char" valign="top" char="." charoff="50">52</td><td align="left" valign="top" charoff="50">PR after C3, had six cycles in total</td></tr><tr><td align="left" valign="top" charoff="50">20</td><td align="char" valign="top" char="." charoff="50">6</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">41</td><td align="left" valign="top" charoff="50">PD after C2</td></tr><tr><td align="left" valign="top" charoff="50">21</td><td align="char" valign="top" char="." charoff="50">6</td><td align="center" valign="top" charoff="50">M</td><td align="char" valign="top" char="." charoff="50">69</td><td align="left" valign="top" charoff="50">PD after C2</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>Patients were recruited at two centres, with different patient number schemes at each center.</p></fn><fn id="tbfnote2"><label/><p>PD=progressive disease; C2=course 2, etc.; CT=computerised tomography scan; MRI=magnetic resonance imaging scan; G4=Grade 4, etc., M=male; F=female; PR=partial response; SD=stable disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Haematological and nonhaematological toxicity by dose level</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Dose level</bold></th><th align="center" valign="top" charoff="50"><bold>No. of patients</bold></th><th align="center" valign="top" charoff="50"><bold>No. of cycles</bold></th><th align="left" valign="top" charoff="50"><bold>Haematological toxicities</bold></th><th align="left" valign="top" charoff="50"><bold>Nonhaem. toxicities</bold></th><th align="left" valign="top" charoff="50"><bold>Best responses</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">1</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">15</td><td align="left" valign="top" charoff="50">G2 neutropaenia</td><td align="left" valign="top" charoff="50">G1 Arthralagia</td><td align="left" valign="top" charoff="50">1 PR</td></tr><tr><td align="left" valign="top" charoff="50">2</td><td align="char" valign="top" char="." charoff="50">4</td><td align="char" valign="top" char="." charoff="50">12</td><td align="left" valign="top" charoff="50">G3 anaemia</td><td align="left" valign="top" charoff="50">Allergic reaction to taxol</td><td align="left" valign="top" charoff="50">1 MR</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">G3 thrombocytopaenia</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">3</td><td align="char" valign="top" char="." charoff="50">2</td><td align="char" valign="top" char="." charoff="50">3</td><td align="left" valign="top" charoff="50">G3 neutropaenia</td><td align="left" valign="top" charoff="50">G2 Arth.</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">4</td><td align="char" valign="top" char="." charoff="50">6</td><td align="char" valign="top" char="." charoff="50">16</td><td align="left" valign="top" charoff="50">G4 neutropaenia &#x000d7; 1; G3 neutropaenia &#x000d7; 1</td><td align="left" valign="top" charoff="50">G2 Arth.</td><td align="left" valign="top" charoff="50">1 MR</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">G3 thrombocytopaenia &#x000d7; 2; G3 anaemia &#x000d7; 1</td><td align="left" valign="top" charoff="50">Allergy to taxol</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">5</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">5</td><td align="left" valign="top" charoff="50">G2 neutropaenia</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">1 SD</td></tr><tr><td align="left" valign="top" charoff="50">6</td><td align="char" valign="top" char="." charoff="50">3</td><td align="char" valign="top" char="." charoff="50">10</td><td align="left" valign="top" charoff="50">G2 neutropaenia &#x000d7; 2</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">1 PR</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote3"><label/><p>PR=partial response; MR=mixed response; SD=stable disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">Temozolomide pharmacokinetic parameters</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="char" char="&#x000b1;"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Dose level</bold></th><th align="char" valign="top" char="&#x000b1;" charoff="50"><bold>Half-life (min)</bold></th><th align="char" valign="top" char="&#x000b1;" charoff="50"><bold>Clearance/<italic>F</italic> (ml&#x02009;min<sup>&#x02212;1</sup>)</bold></th><th align="char" valign="top" char="&#x000b1;" charoff="50"><bold>Volume of distribution/<italic>F</italic> (l)</bold></th><th align="char" valign="top" char="&#x000b1;" charoff="50"><bold>AUC day 1 (<italic>&#x003bc;</italic>g&#x02009;ml<sup>&#x02212;1</sup>&#x02009;min<sup>&#x02212;1</sup>)</bold></th><th align="center" valign="top" charoff="50"><bold>AUC day 5 (<italic>&#x003bc;</italic>g&#x02009;ml<sup>&#x02212;1</sup>&#x02009;min<sup>&#x02212;1</sup>)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">1 (<italic>n</italic>=3) (100&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup>)</td><td align="char" valign="top" char="&#x000b1;" charoff="50">98&#x000b1;20</td><td align="char" valign="top" char="&#x000b1;" charoff="50">157&#x000b1;10</td><td align="char" valign="top" char="&#x000b1;" charoff="50">22.2&#x000b1;5.9</td><td align="char" valign="top" char="&#x000b1;" charoff="50">1064&#x000b1;3</td><td align="center" valign="top" charoff="50">921<sup>a</sup></td></tr><tr><td align="left" valign="top" charoff="50">2 (<italic>n</italic>=1) (150&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup>)</td><td align="char" valign="top" char="." charoff="50">241</td><td align="char" valign="top" char="." charoff="50">157</td><td align="char" valign="top" char="&#x000b1;" charoff="50">54</td><td align="char" valign="top" char="." charoff="50">1501</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">3&#x02013;6 (<italic>n</italic>=14) (200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup>)</td><td align="char" valign="top" char="&#x000b1;" charoff="50">122&#x000b1;55</td><td align="char" valign="top" char="&#x000b1;" charoff="50">188&#x000b1;55</td><td align="char" valign="top" char="&#x000b1;" charoff="50">30.5&#x000b1;5.5</td><td align="char" valign="top" char="&#x000b1;" charoff="50">2106&#x000b1;608</td><td align="center" valign="top" charoff="50">1946&#x000b1;580 (<italic>n</italic>=11)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote4"><label/><p><italic>F</italic> indicates bioavailability, which is not determined here.</p></fn><fn id="tbfnote5"><label/><p>AUC is the area under the plasma concentration&#x02013;time curve.</p></fn><fn id="tbfnote6"><label>a</label><p>Data available on only one patient at this dose level.</p></fn><fn id="tbfnote7"><label/><p>One patient at 200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> had anomalous data, with increasing plasma concentrations throughout the sampling period.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p content-type="table-title">Paclitaxel pharmacokinetic parameters</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Dose level</bold></th><th align="center" valign="top" charoff="50"><bold>Half-life (min)</bold></th><th align="center" valign="top" charoff="50"><bold>Clearance (ml&#x02009;min<sup>&#x02212;1</sup>)</bold></th><th align="center" valign="top" charoff="50"><bold>Volume of distribution (litres)</bold></th><th align="center" valign="top" charoff="50"><bold>AUC (<italic>&#x003bc;</italic>g&#x02009;ml<sup>&#x02212;1</sup>&#x02009;min<sup>&#x02212;1</sup>)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">1 (150&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>)</td><td align="center" valign="top" charoff="50">470, 522</td><td align="center" valign="top" charoff="50">364, 430</td><td align="center" valign="top" charoff="50">247, 324</td><td align="center" valign="top" charoff="50">632, 600</td></tr><tr><td align="left" valign="top" charoff="50">2 (150&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>)</td><td align="center" valign="top" charoff="50">502, 383</td><td align="center" valign="top" charoff="50">652, 513</td><td align="center" valign="top" charoff="50">473, 283</td><td align="center" valign="top" charoff="50">359, 480</td></tr><tr><td align="left" valign="top" charoff="50">3 (150&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>)</td><td align="center" valign="top" charoff="50">550, 412, 105<sup>a</sup></td><td align="center" valign="top" charoff="50">779, 909, 505<sup>a</sup></td><td align="center" valign="top" charoff="50">619, 540, 76<sup>a</sup></td><td align="center" valign="top" charoff="50">385, 300, 523<sup>a</sup></td></tr><tr><td align="left" valign="top" charoff="50">4 (175&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>)</td><td align="center" valign="top" charoff="50">410&#x000b1;74</td><td align="center" valign="top" charoff="50">373&#x000b1;100</td><td align="center" valign="top" charoff="50">216&#x000b1;53</td><td align="center" valign="top" charoff="50">858&#x000b1;255</td></tr><tr><td align="left" valign="top" charoff="50">5 (200&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>)</td><td align="center" valign="top" charoff="50">495, 198<sup>a</sup></td><td align="center" valign="top" charoff="50">320, 717<sup>a</sup></td><td align="center" valign="top" charoff="50">228, 205<sup>a</sup></td><td align="center" valign="top" charoff="50">1162, 544<sup>a</sup></td></tr><tr><td align="left" valign="top" charoff="50">6 (225&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>)</td><td align="center" valign="top" charoff="50">298&#x000b1;87</td><td align="center" valign="top" charoff="50">363&#x000b1;120</td><td align="center" valign="top" charoff="50">152&#x000b1;63</td><td align="center" valign="top" charoff="50">1220&#x000b1;416</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote8"><label>a</label><p>Data only to 8&#x02009;h.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>


